Brief: Natural products are an unsurpassed source of chemical diversity and an ideal starting point for any screening program for pharmacologically active small molecules. Historically, natural products have been the most successful source of new drugs.From 1981 to date, 79 (80%) out of 99 small molecule anticancer drugs are natural product-based/inspired, with 53 (53%) being either natural products or derived therefrom. Natural products have been proven to be successful modulators of difficult targets such as a range of antibacterial targets and, especially, protein�Cprotein interactions. Furthermore, many researchers consider natural products and their derivatives as a privileged tools for the study and manipulation of protein function. The SABsNatural Product Monomers (HTS) Library, a unique collection of 1680 natural products with known bioactivity, wide source, and high cost effectiveness, is a powerful tool for drug discovery, pharmacological study, and stem cell differentiation, etc

Brief: The blood�Cbrain barrier (BBB) is a highly selective semipermeable border that separates the circulating blood from the brain and extracellular fluid in the central nervous system (CNS). In its neuroprotective role, the blood�Cbrain barrier functions to hinder the delivery of many potentially important diagnostic and therapeutic agents to the brain. Overcoming the difficulty of delivering therapeutic agents to specific regions of the brain presents a major challenge to treatment of most brain disorders. Choosing the compounds that could penetrate BBB into the compound library targeting CNS is critical for CNS drug discovery. Based on the scientific literature, SAB collects 320 out of 5000 compounds as CNS-Penetrant Compound Library, which can be used for CNS-Penetrant related research and drug screening for CNS diseases

Brief: Scientists already found that the isomers or metabolites of many existing drugs show biological activity. For example, Levopropoxypheneis anantitussive, approved by FDA, but its enantiomer,Dextropropoxyphene, has an analgesic effect; L-sotalol is alpha-blocker while d-sotalol is antiarrythmic. Currently, knowledge of isomerism has helped us in introducing safer and more effective drug alternatives of the newer as well as existing drugs.These compounds that have rich pharmacological evaluation data are ideal as entry point for drug repurposing. The SABsSelected drug metabolites/isomers Library, a unique collection of 200 drug isomers/metabolites with a great diversity, can be used for drug screening

Brief: Fragment-based drug discovery (FBDD) has emerged in the past decade as a powerful tool for discovering drug leads. FBDD has played a role in discovery of at least 30 drugs that are in various stages of clinical development, and practitioners of FBDD can be found throughout the world in both academia and industry.Different from HTS, FBDD finds fragment-like hits (molecular weight less than 300) that usually bind with low affinity; therefore, sensitive detection methods are required, such as sensitive biophysical techniques: X-ray crystallography, NMR, Surface Plasmon Resonance (SPR), or mass spectrometry. This strategy offers several attractive features compared with traditional HTS or virtual screening, including higher hit rate, higher binding efficiency, and providing multiple starting points for further structural optimizations. In addition, because of the exponentially growing amount of information about one certain target, the effective utilization of bioinformatics and chemoinformatics is expected to contribute markedly toward the discovery of new drugs. The SAB sFragment Library collects 246 fragment-like small molecules for drug discovery

Brief: SABs Killer Collections include 277 synthetic and natural toxic substances that can alter cellular, metabolic and membrane functions, such as DNA/ RNA synthesis inhibitors, cytotoxic agents, immune suppressants, anti-proliferatives, endocrine disruptors and other agents. This special collection finds application in testing the sensitivity, development and profiling of new assays in high throughput screening (HTS) programs used in new drug discovery

Brief: Cardiovascular disease generally refers to all types of diseases that affect the heart or blood vessels, including coronary heart disease (clogged arteries), which can cause heart attacks, stroke, congenital heart defects and peripheral artery disease, and is the leading cause of death for men and women in the U.S. Different types of cardiovascular diseases have different mechanisms of pathogenesis. Antioxidants, lipid-lowering agents, anti-ischemic drugs, and platelet aggregation inhibitors all can reduce cardiovascular disease risk. Some natural products can inhibit the gene expression of cell adhesion molecules, cytokine, and chemokine, inhibit the function of platelet, enhance the release of nitric oxide by endothelial cells, and inhibit the contraction of smooth muscle. A unique collection of 515 cardiovascular diseases related compounds by SAB can be used for cardiovascular diseases related research and high throughput and high content screening for new drugs

Brief: Metabolism is the set of life-sustaining chemical reactions involved in maintaining the living state of the cells and the organism, including catabolism and anabolism, and is one way the body maintainshomeostasis. The main focus in metabolism research area is the biological regulatory mechanism and its role in obesity, diabetes, cardiovascular diseases, and cancer. The unique collection of 816 small chemicals targeting metabolism diseases will provide the support for metabolism research and related drug screening.

Brief: Fluorine atoms have a unique combination of electronic and physical properties. As such, when incorporated into active pharmaceutical ingredients (APIs), fluorine atoms often influence their protein binding affinity and lipophilicity but not the shape of the resulting fluorochemicals. Fluorination can thus significantly impact the bioavailability or metabolic stability of drug substances. The pivotal role that the element fluorine plays in modulating the properties of bioactive molecules is reflected by the growth of its presence in approved drugs, as evidenced by the fact that between 15% to 20% of all medicines and agrochemicals on the market contain at least one fluorine atom in their structure. As of 2009, the FDA had approved >140 fluorine-containing drugs, such as fluorouracil, Miglitol, Gemcitabine, Sofosbuvir, atorvastatin, fluoxetine, ciprofloxacin, etc. The judicious introduction of fluorine into a molecule can productively influence conformation, pKa, intrinsic potency, membrane permeability, metabolic pathways, and pharmacokinetic properties. Nowadays, the application of specialty fluorochemicals in the pharmaceutical industry has been increasingly widespread. SABs fluorochemical library has become an effective tool for developing new anticancer drugs, anesthetics, antidepressants, antifungals, antiviral drugs, antibiotics, cholesterol lowering agents, and anti-inflammatory agents. In addition, in agricultural uses, the addition of fluorine to many agricultural herbicides, pesticides, and fungicides improves the potency and therefore reduces the required application rate of these substances

Brief: Cardiotoxicity is one of the leading causes of drug attrition during development, and accounts for 22-28% of US post-marketing drug withdrawal. Therefore, developing sensitive in vitro assays assessing drug-induced cardiotoxicity in preclinical and early clinical stages is especially important for drug development. The SABsCardiotoxicity Compound Library, a unique collection of 132 cardiotoxicity inducing compounds, can be used for chemical toxicity evaluation and prediction

Brief: Angiogenesis is a normal and vital process in growth and development, as well as inwound healingand in the formation ofgranulation tissue. However, uncontrolled angiogenesis underlies many deadly and debilitating conditions, including cancer, skin diseases, immune disorders, diabetic ulcers, cardiovascular disease, stroke, critical limb ischemia, and many others. Therefore, angiogenesis has become an attractive target for combating diseases characterized by either poor vascularization or abnormal vasculature. For example, angiogenesis plays a critical role in the growth of cancer. Tumors induce blood vessel growth (angiogenesis) by secreting various growth factors (e.g.VEGF) and proteins which induce capillary growth into the tumor, providing it with oxygen and nutrients.Angiogenesis is also required for the spread of a tumor, ormetastasis. Therefore, angiogenesis inhibitors can be used to treat cancer. In addition, proangiogenic therapies are being explored as options to treat ischemiccardiovascular diseases by formation of ��natural bypasses����that is, collateral vessels. The SABsAngiogenesis related Compound Library, a unique collection of angiogenesis related compounds, can be used for research in angiogenesis and related drug discovery